Cognitive impairment, anxiety, and depression in patients with chronic lymphoproliferative diseases
Year: 2021, volume 17 Issue: №1 Pages: 151-155
Heading: Тhematic supplement Article type: Original article
Authors: Teregulova D.R., Akhmadeeva L.R., Bakirov B.A.
Organization: Bashkir State Medical University of the Russian Health Care
Heading: Тhematic supplement Article type: Original article
Authors: Teregulova D.R., Akhmadeeva L.R., Bakirov B.A.
Organization: Bashkir State Medical University of the Russian Health Care
Summary:
Objective: to assess the prevalence of cognitive and affective impairment in patients with chronic lymphoproliferative diseases. Material and Methods. 130 patients (59 women and 71 men) aged 42 to 86 years were examined, including 62 patients with chronic lymphocytic leukemia and 68 with multiple myeloma. The Montreal Cognitive Assessment Scale (MoCA) was used to assess cognitive impairment, and the Hospital Anxiety and Depression Scale (HADS) was used to assess affective impairment. Results. We diagnosed cognitive impairment (MoCA<26) in 78.5% out of 130 patients, while only 33.9% complained of memory loss. The average score on the MoCA scale was 23 [20; 25] points. The level of education and age of the patients influenced the MoCa indices. Almost one third (38 out of 126 patients) had symptoms of subclinical anxiety by HADS, 28 (22.2%) patients had clinical anxiety. Forty six (36.5%) patients had symptoms of subclinical depression by HADS, 23(18.3%) patients had clinical depression. Anxiety rates were higher in women and elderly patients. Conclusion. Most patients had cognitive decline. The development of cognitive impairment in patients is influenced by age, educational level, and affective disorders. Every second patient has manifestations of anxiety and depression of varying severity, while the level of anxiety is higher in women and elderly patients.
Bibliography:
1. Bakirov BA, Latypova LF. The incidence and prevalence of chronic lymphocytic leukemia among the adult population of the Republic of Bashkortostan. Creative Surgery and Oncology 2012; 1: 17-22.
2. Bakirov BA, Kalimullina DKh, Bakirov АВ, et al. Prevalence and prognostic value of molecular genetic markers in multiple myeloma and chronic lymphocytic leukemia. Ufa: Mir pechati, 2009; 104 p.
3. Teregulova DR, Bakirov BA, Akhmadeeva LR. The influence of polychemotherapy on cognitive functions in patients with lymphoproliferative diseases. Perm Medical Journal 2018; 35 (6): 73-81.
4. Gulen НК, Yildirim A, Emre U, et al. Evaluation of MoCA Scale Ratings with Cognitive Level Correlation in Mild Cognitive Disorders. Istanbul Medical Journal 2017; 18 (1):18-22.
5. Dyakonov IF, Ovchinnikov BV. Psychological diagnostics in the practice of a doctor. SPb.: SpecLit, 2008; 148 p.
6. Novik АА, lonova Tl. Quality of life research in hematooncology. Clinical Oncohematology 2008; 1 (2): 168-73.
7. Rebrova OYu. Statistical analysis of medical data: Application of the Statistica software package. Moscow: Mediasphere, 2006; 312 p.
8. Strati Р, Uhm JH, Kaufmann TJ, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 2016; 101 (4): 458-65.
9. Mohammadi M, Cao Y, Glimelius I, et al. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma: a Swedish population-based study. ВМС Cancer 2015; 15: 850.
10. Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, et al. Neurotoxicity in breast cancer survivors >10 years post-treatment is dependent on treatment type. Brain Imaging Behav 2015;9:275-84.
11. Aiki S, Okuyama T, Sugano K, et al. Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors. Jpn J Clin Oncol 2018; 48(1): 61-7.
12. Vichaya EG, Wang XS, Sailors MH, et al. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer 2013; 119 (23): 4188-95.
13. Wouters H, Baars JW, Schagen SB. Neurocognitive function of lymphoma patients after treatment with chemotherapy. Acta Oncologica 2016; 55 (9-10): 1121-5.
| Attachment | Size |
|---|---|
| 2021_01-1_151-155.pdf | 398.32 KB |
Русский
English